Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.

Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, Dominik R, Key NS, Parise LV, Ataga KI.

Thromb Res. 2013 Sep;132(3):341-5. doi: 10.1016/j.thromres.2013.08.002. Epub 2013 Aug 8.

2.

Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF; DeNOVO Investigators.

JAMA. 2011 Mar 2;305(9):893-902. doi: 10.1001/jama.2011.235.

3.

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.

Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, Harrington RA.

Ann Thorac Surg. 2000 Sep;70(3):866-71; discussion 871-2.

PMID:
11016325
4.
5.

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.

N Engl J Med. 1998 Aug 13;339(7):436-43.

6.

Phase I study of eptifibatide in patients with sickle cell anaemia.

Lee SP, Ataga KI, Zayed M, Manganello JM, Orringer EP, Phillips DR, Parise LV.

Br J Haematol. 2007 Nov;139(4):612-20. Epub 2007 Oct 3.

PMID:
17916103
8.

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ.

J Hematol Oncol. 2013 Feb 17;6:17. doi: 10.1186/1756-8722-6-17.

9.

Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial.

Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM.

JAMA. 2001 Nov 7;286(17):2099-106.

PMID:
11694150
10.

Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators.

Marso SP, Bhatt DL, Roe MT, Houghtaling PL, Labinaz M, Kleiman NS, Dyke C, Simmoons ML, Califf RM, Harrington RA, Topol EJ.

Circulation. 2000 Dec 12;102(24):2952-8.

11.

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

Adeoye O, Knight WA, Khoury J, Schmit PA, Sucharew H, Broderick JP, Pancioli AM; CLEAR-ER Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e313-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.012. Epub 2014 Feb 15.

12.

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial).

JAMA. 2001 May 16;285(19):2468-73.

PMID:
11368699
13.

Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study.

Gokhroo R, Kishor K, Ranwa B, Bisht DS, Gupta S, Anantharaj A.

Cardiovasc Ther. 2015 Aug;33(4):155-60. doi: 10.1111/1755-5922.12123.

PMID:
25892271
14.

Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study.

Ronner E, van Kesteren HA, Zijnen P, Altmann E, Molhoek PG, van der Wieken LR, Cuffie-Jackson CA, Neuhaus KL, Simoons ML.

Eur Heart J. 2000 Sep;21(18):1530-6.

PMID:
10973767
15.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.

N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.

16.

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.

Jakubowski JA, Zhou C, Winters KJ, Lachno DR, Howard J, Payne CD, Mant T, Jurcevic S, Frelinger AL 3rd.

Platelets. 2015;26(5):474-9. doi: 10.3109/09537104.2014.940887. Epub 2014 Aug 20.

PMID:
25140584
18.

RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study.

Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edwards S, Bustrack J, Emanuele M.

Blood. 1997 Sep 1;90(5):2041-6.

19.

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gilchrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators.

JAMA. 2002 Feb 6;287(5):618-21.

PMID:
11829701
20.

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.

Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators.

Stroke. 2008 Dec;39(12):3268-76. doi: 10.1161/STROKEAHA.108.517656. Epub 2008 Sep 4.

Supplemental Content

Support Center